Laverock Therapeutics

Laverock Therapeutics is a UK biotechnology company developing gene-silencing medicines using RNA interference (RNAi) and related oligonucleotide-based technologies. RNAi therapeutics work by introducing synthetic RNA molecules that bind to and degrade specific messenger RNA sequences, preventing the production of disease-causing proteins. The approach has attracted significant pharmaceutical industry investment after the first generation of approved RNAi drugs demonstrated durable clinical efficacy, particularly in rare genetic diseases and cardiovascular conditions. Laverock focuses on identifying targets where conventional small-molecule drugs have failed or where RNAi offers a superior duration of effect.

In June 2026, Laverock Therapeutics received a £2.2m Innovate UK grant awarded on 1 June 2026, providing public research and development funding to advance its pipeline. The award reflects Innovate UK's continued support for UK biotech companies working on next-generation therapeutic modalities at a stage where clinical-development capital remains scarce and grant funding is critical to de-risking early programmes before Series A fundraising.

Laverock's Innovate UK award places it within a cohort of UK biotechs receiving public support during a period when the grant count has fallen to a ten-year low across the wider innovation economy, making individual awards more significant for the companies that receive them. The gene-silencing therapeutic area has seen growing commercial validation globally, and UK companies like Laverock are competing with US and European peers for both talent and investor attention.